Regeneron revenue beats estimates on strong sales of Eylea, COVID therapy
Reuters
Published Feb 04, 2022 06:38AM ET
Updated Feb 04, 2022 07:55AM ET
(Reuters) -Regeneron Pharmaceuticals Inc on Friday reported fourth-quarter revenue that beat analysts' estimates, boosted by demand for blockbuster drugs Dupixent and Eylea, coupled with higher sales of its COVID-19 therapy.
Sales of Dupixent, which is used to treat eczema, jumped 51% to $1.77 billion, while that of eye drops Eylea increased 13% to $2.45 billion.
The company also recorded $2.30 billion in sales of its COVID-19 antibody therapy, REGEN-COV, as it completed final deliveries to the U.S. government under an agreement signed in September.
That helped its quarterly revenue more than double to $4.95 billion, and beat analysts estimates of $4.51 billion, as per Refinitiv IBES data. Excluding revenue from REGEN-COV, the sales growth was 17%.
The U.S. Food and Drug Administration in January had revised its emergency use authorizations for COVID-19 antibody treatments from Regeneron (NASDAQ:REGN) and Eli Lilly (NYSE:LLY) to limit their use, as the drugs were found to be unlikely to work against the Omicron variant.
"Given the lack of efficacy of REGEN-COV against the Omicron variant, we are working hard to develop next generation antibodies that are active against Omicron and all other variants of concern," said Leonard Schleifer, president and chief executive officer of Regeneron.
The company's net profit nearly doubled to $2.23 billion, or $19.69 per share, in the fourth quarter ended Dec. 31.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.